Endo Retained Earnings (Accumulated Deficit) 2024-2025 | NDOI

Endo retained earnings (accumulated deficit) from 2024 to 2025. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.

Endo Retained Earnings (Accumulated Deficit) 2024-2025 | NDOI

Endo retained earnings (accumulated deficit) from 2024 to 2025. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$75.5B
Zoetis (ZTS)$67.5B
Takeda Pharmaceutical (TAK)$46.8B
Daiichi Sankyo, - (DSNKY)$44.2B
BeOne Medicines - (ONC)$30.6B
Sandoz Group AG (SDZNY)$24.9B
Summit Therapeutics (SMMT)$21B
Merck (MKKGY)$16.7B
Shionogi (SGIOY)$14.2B
United Therapeutics (UTHR)$13.4B
Neurocrine Biosciences (NBIX)$13.2B
Orion OYJ (ORINY)$11B
IPSEN (IPSEY)$10.2B
Stevanato Group S.p.A (STVN)$7.7B
Corcept Therapeutics (CORT)$7.7B
Madrigal Pharmaceuticals (MDGL)$7.7B
Grifols, S.A (GRFS)$6.9B
Ionis Pharmaceuticals (IONS)$6.8B
Hikma Pharmaceuticals Plc (HKMPF)$6.2B
Ono Pharmaceutical (OPHLF)$5.2B
Soleno Therapeutics (SLNO)$4.3B
Hypermarcas (HYPMY)$3.2B
Crinetics Pharmaceuticals (CRNX)$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.6B
NewAmsterdam Pharma (NAMS)$2.3B
Centessa Pharmaceuticals (CNTA)$2.1B
BioCryst Pharmaceuticals (BCRX)$1.8B
Ocular Therapeutix (OCUL)$1.8B
ARS Pharmaceuticals (SPRY)$1.8B